fig6

Engineering a keloid-like fibrotic skin-on-a-chip for drug evaluation

Figure 6. Expression of specific proteins and inflammatory factors in the normal group, keloid SoC model group, and model groups treated with nintedanib or 5-FU. (A) Induction and drug intervention process in keloid SoC. Created with BioRender.com; (B) IHC for pro-Col I, and IF staining for Col III (green), Vimentin (red), α-SMA (green), and DAPI (blue). Scale bar: 100 μm; (C) Quantification of pro-Col I/Col III ratio and fluorescence intensities of pro-Col I, Col III, Vimentin, and α-SMA. Analyses are based on technical replicates (n = 3 wells); (D) Changes in inflammatory factor levels: IL-6, TNFα, IL-8, VEGF-A, IL-1α, and IL-1β. Analyses are based on technical replicates (n = 3 wells). Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. SoC: Skin-on-chip; 5-FU: 5-fluorouracil; IHC: immunohistochemistry; IF: immunofluorescence; α-SMA: α-smooth muscle actin; DAPI: 4′,6-diamidino-2-phenylindole; IL-6: interleukin-6; TNFα: tumor necrosis factor-alpha; IL-8: interleukin-8; VEGF-A: vascular endothelial growth factor A; IL-1α: interleukin-1 alpha; IL-1β: interleukin-1 beta; ANOVA: analysis of variance; TGF-β: transforming growth factor-beta; NDNB: Nintedanib.